Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 5,000 people, planned
- Starts
- Dec 2026
- Expected to end
- Dec 2032
- Type of study
- Observational
- Treatments tested
- The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥18 years
- Diagnosis of prostate cancer documented in the institutional medical record. Prostate adenocarcinoma will constitute the principal analytic population, while other prostate cancer histology's may be retained for descriptive background analyses when clinically relevant
- Evaluation, diagnosis, treatment, or follow-up within or beyond Advocate Health Wake Forest Baptist / Wake Forest University School of Medicine and availability of sufficient clinical information for at least one study objective
- For the prospective component, first ascertainment after protocol activation will be conducted through routine clinical records or institutional clinical data systems
- For the historical background component, available institutional records predating protocol activation will be used to characterize prostate cancer presentation, management, and outcomes
Who cannot take part
- Insufficient clinical information to establish the relevant diagnosis, treatment, or outcome for a proposed analysis
- Records that cannot be used under applicable institutional privacy, data-governance, or IRB requirements
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesContact: Sachin Vyas, MS, PhDNot yet recruiting
About the trial
What the trial wants to find out
Management of prostate cancer increasingly integrates conventional clinicopathologic risk factors with multiparametric magnetic resonance imaging (mpMRI), targeted and systematic biopsy, molecular imaging, and selected tissue-based genomic biomarkers. Contemporary guidelines emphasize risk-adapted shared decision-making and allow selective use of tissue-based genomic biomarkers when additional risk stratification may alter management discussions.
The group in the trial
- Patients been diagnosed with the prostate cancer
To determine how clinically obtained tumor genomic and transcriptomic features, phenotype, real-world treatment selection, and longitudinal oncologic outcomes
Treatment: The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ICEBERG-PC: Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer: A Single-Site AmbidirectionalObservational Outcomes Cohort
- Record updated
- 16 November 2026